Cortex gets OK to resume enrollment for Ampakine trials
July 17 (Reuters) - Cortex Pharmaceuticals Inc. (COR.A: Quote, Profile, Research) said it has received approval from U.S. regulators to resume enrollment for clinical trials of its drug candidate, Ampakine CX717, in Alzheimer PET-scan studies .
The trial will resume at all dose levels.
The study of Ampakine CX717, which was originally designed with doses of 200mg, 600mg and 1200mg, was placed on hold by the U.S. Food and Drug Administration due to concerns over some preclinical animal data. (Reporting by Shailesh Kuber in Bangalore)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Showbiz week
Death toll soars in Myanmar